Navigation Links
NxStage Reports First Quarter 2013 Financial Results
Date:5/2/2013

olidated Statements of Comprehensive Loss
(in thousands, except per share data)
(unaudited)Three Months Ended
March 31,  20132012Revenues

$
,644$
56,951Cost of revenues

37,64435,639Gross profit

24,00021,312Operating expenses:Selling and marketing

10,6969,920Research and development

5,1083,897Distribution

4,9084,532General and administrative

7,8246,622Total operating expenses

28,53624,971Loss from operations

(4,536)(3,659)Other expense:Interest expense

(150)(1,193)Other expense, net

(176)(52)(326)(1,245)Net loss before income taxes

(4,862)(4,904)Provision for income taxes

132240Net loss

$   (4,994)$
(5,144)Net loss per share, basic and diluted

$
(0.08)$
(0.09)Weighted-average shares outstanding, basic and diluted

59,38155,773Other comprehensive gain

145173Total comprehensive loss

$   (4,849)$
(4,971) NxStage Medical, Inc.Condensed Consolidated Balance Sheets(in thousands, except share data)(unaudited)March 31,December 31,20132012ASSETSCurrent assets:Cash and cash equivalents

$

99,803$

106,439Accounts receivable, net

22,05818,990Inventory

36,96633,504Prepaid expenses and other current assets

4,8252,534Total current assets

163,652161,467Property and equipment, net

37,31736,320Field equipment, net

10,29710,101Deferred cost of revenues

36,13538,028Intangible assets, net

19,12019,819Goodwill

42,42142,421Other assets

3,2613,793Total assets

$

312,203$

311,949LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable

$

20,593$

16,645Accrued expenses

19,56120,400Other current liabilities

2,1652,187Total current liabilities

42,31939,232Deferred revenues

'/>"/>
SOURCE NxStage Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. NxStage Announces FDA Clearance for New High Flow Capabilities with NxStage System One
2. NxStage Names Robert G. Funari Chairman Of The Board
3. NxStage Completes Move to Direct Sales In UK
4. NxStage Educational Reception at Annual Dialysis Conference Features Celebrity and Former NxStage User Stephen Furst
5. NxStage Reports Record Fourth Quarter and Full-Year 2012 Financial Results
6. NxStage Announces CE Mark Approval, First Clinical Use of its Single Needle for Dialysis Patients
7. NxStage Announces CE Mark Approval for New High Flow Capabilities with System One
8. NxStage Announces CE Mark Approval for Nocturnal Home Hemodialysis
9. NxStage Initiates 2013 Call to Action Campaign with Launch of Hemodialysis At Home: A Better Way For a Better Life
10. NxStage Home Hemodialysis Patient Awareness Tour Kicks Off January 29th
11. Robert Funari Joins NxStage Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014 ... today announced that it has taken an exclusive worldwide ... FScan Ltd, a Durham University ... Pharma will pay an upfront fee, development and commercial ... Pharma has also taken an option for additional exclusive ...
(Date:7/28/2014)... Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH ), today announced ... June 30, 2014. Net loss for the ... to $8.3 million for the same period in 2013. The ... decrease in interest expense in the current period.  ... 2014 was $15.2 million, compared with net loss of $15.9 ...
(Date:7/28/2014)... YORK , July 28, 2014 Reportbuyer.com ... Global Bone Densitometers Market 2014-2018 ... A bone densitometry scan is a special type of ... a bone. It is used primarily to detect osteopenia ... low and the risk of fractures is high. The ...
Breaking Medicine Technology:Glide Pharma Takes Exclusive Worldwide Rights to Novel Diagnostic Technology for Prostate Cancer 2Glide Pharma Takes Exclusive Worldwide Rights to Novel Diagnostic Technology for Prostate Cancer 3Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 2Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 3Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 4Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 5Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 6Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 7Global Bone Densitometers Market 2014-2018 2Global Bone Densitometers Market 2014-2018 3Global Bone Densitometers Market 2014-2018 4Global Bone Densitometers Market 2014-2018 5
... MonoSol Rx, LLC ("MonoSol Rx"), the developer of PharmFilm® ... Inc., a wholly-owned subsidiary of Reckitt Benckiser Group plc ... market adoption of Suboxone® (buprenorphine HCl/naloxone HCl dihydrate) sublingual ... announcement of full-year 2010 financial results. ...
... Feb. 22, 2011 Prasco Laboratories ... supply agreement with Shire US Manufacturing, Inc. for ... Prasco, LLC is prepared to market the authorized ... Shire,s request, immediately upon any entrance into the ...
Cached Medicine Technology:MonoSol Rx, LLC Announces Suboxone Sublingual Film Achieves 25% Share of Total U.S. Suboxone Market Volume at Year-End 2010 2MonoSol Rx, LLC Announces Suboxone Sublingual Film Achieves 25% Share of Total U.S. Suboxone Market Volume at Year-End 2010 3
(Date:7/29/2014)... New Haven, CT (PRWEB) July 29, 2014 ... head up its Client Services Operation. , Christina Upton, ... been named Director of Client Services responsible for managing ... , Client Services is at the center of all ... the most well-known brands in the world . The ...
(Date:7/29/2014)... 1WorldSync announces B. Braun Melsungen AG, ... utilize the Global Data Synchronization Network™ (GDSN®) standard ... product information with the U.S. Food and Drug ... global supply chain. Holger Clobes, Head of Global ... Braun serves customers in 61 countries, among others ...
(Date:7/29/2014)... Collierville, TN (PRWEB) July 29, 2014 ... to the reimbursement model of all hospitals. Studies show ... tsunami.[1] One simple, easy, low cost tool that ... organizational performance by 20 to 25%. , Their secret? ... to one anther at the end of an operational ...
(Date:7/29/2014)... Doheny HealthDay Reporter , MONDAY, ... risk of cardiovascular disease may be able to take hormone ... harming their hearts, according to a new study. Previous ... replacement therapy had harmful effects on the heart. But, many ... treatments, and much further past menopause. In this ...
(Date:7/29/2014)... San Francisco, California (PRWEB) July 29, 2014 ... to reach USD 9,542.3 million by 2020, growing at ... according to a new study by Grand View Research, ... acceptance of these devices by the geriatric population, along ... are some of the major drivers of this market. ...
Breaking Medicine News(10 mins):Health News:CRN International Names New Director to Lead Client Services Department 2Health News:B. Braun Selects 1WorldSync Unique Device Identification and Product Information Solution 2Health News:B. Braun Selects 1WorldSync Unique Device Identification and Product Information Solution 3Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 2Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 3Health News:Early Hormone Therapy May Be Safe for Women's Hearts 2Health News:Early Hormone Therapy May Be Safe for Women's Hearts 3Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 2Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 3Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 4Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 5Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 6
... Human Services reported that very little precautionary measures can be ... flu) // . The infection in humans is actually caused ... ,Hence to prevent the global pandemic it has issued various ... a global pandemic. The government says that as such ...
... Guarraci, an assistance professor of psychology at south-western university and ... has a greater effect on the sexual behaviour of female ... and is among the first to determine the effects of ... also probes into the relationship between caffeine and sex. ...
... press that all the medical expenditures of pregnant women will be ... ,This plan is introduced mainly to ensure proper ... six months this plan will add $5 million to the annual ... the amount of expenditure of the rural women by $18. The ...
... of lives ever year. The need the organ, kidney is on ... ,Of all the organ transplantations done, kidney transplantation accounts ... sudden fall in the number of people who come forward to ... of the patients to undergo kidney transplants has widened to more ...
... Science Museum in London has found a unique way to help ... people the much-needed dose of light // . ,The ... of dark winter days. ,Up to 500,000 people, a ... seasonal affective disorder. SAD is more common in the northern ...
... an 8% increase in its share, following approval of Vivagel ... of HIV. // The company even signed a $20 ... and Infectious Diseases, an integral part of the National Institute ... for the prevention of HIV infection. The FDA recognizes the ...
Cached Medicine News:Health News:Starpharma Develops New Gel (Vivagel) To Prevent HIV Transmission 2
The Advance revision knee system was designed to address the unpredictable nature of revision knee arthroplasty by providing a wide variety of implant and instrument options....
... CRA femoral component is intended for ... and varus/valgus ligament stability, yet require ... inadequate bone stock. The NexGen CRA ... PMMA precoat surface. This device is ...
... manufacturers focus attention on implant design, one ... Profix Total Knee System seeks to establish ... system and the tools to implant them. ... recognized for innovation in total knee instrumentation, ...
Cruciate retaining, posterior stabilized and constrained components....
Medicine Products: